At a glance
ClinicalIndex Comparison RecordN/ACompleted· 113,035 enrolled
Drug / intervention
rt-PAdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Characteristics and In-hospital Outcomes of Chinese Elderly (>80 Years) Patients With Acute Ischemic Stroke Receiving Intravenous Recombinant Tissue Plasminogen Activator Treatment Within 4.5 Hours of Symptom Onset
In Brief
An observational study evaluating rt-PA for Stroke. Completed, enrolled 113,035 participants across 1 site.
Detailed Summary
The objective of the study is to find out the in-hospital clinical outcomes among Chinese Acute Ischaemic Stroke (AIS) patients, who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of symptom onset in different age groups (18 to 80 years and above 80 years).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedMay 2022
Enrollment StartNov 2022
Primary CompletionMar 2023
TodayJul 2026
First PostedMay 27, 2022
Enrollment StartNov 30, 2022
Primary CompletionMar 28, 2023
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.1 years ago
Interventions
rt-PAdrug
Intravenous recombinant tissue plasminogen activator (IV rt-PA)